Myriad Genetics Inc

Most Recent

  • uploads///AdobeStock_
    Company & Industry Overviews

    Myriad Genetics Up after UnitedHealth’s Favorable Decision

    Yesterday, Myriad Genetics submitted an 8K filing with the SEC announcing a favorable coverage decision by UnitedHealth Group.

    By Margaret Patrick
  • uploads///FEI
    Company & Industry Overviews

    Myriad Stock Rose on FDA Supplementary Premarket Approval

    On June 18, Myriad Genetics stock rose ~1.9% after the FDA accepted its BRACAnalysis CDx test for review.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Vectra DA Could Be Solid Growth Driver for Myriad Genetics in 2018

    In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) Vectra DA test reported revenues close to $16 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Saw Positive Results from GeneSight Trial

    Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018

    In fiscal 2018, Myriad Genetics (MYGN) expects to witness rapid expansion in reimbursement for GeneSight based on positive results of the 1,200-patient pharmacogenomic study.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?

    In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    EndoPredict Posted Robust Demand Trends in US in Fiscal 1Q18

    Myriad Genetics (MYGN) estimated the total addressable market size of its next-generation RNA expression test to be close to $0.9 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Disease-Specific Panels Key to Myriad Genetics’ Growth Strategy

    Myriad Genetics (MYGN) reported 40% year-over-year growth in volumes of disease-specific panels sold in fiscal 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Could Boost Adoption of Prolaris in 2018?

    In the first quarter of 2018, Myriad Genetics’ (MYGN) Prolaris reported revenues close to $2.9 million, which is flat growth on a year-over-year (or YoY) basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication

    On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Companion Diagnostics May Be Major Opportunity for Myriad Genetics

    Myriad Genetics (MYGN) expects to attain a penetration level of 4% in the companion diagnostics segment by 2020.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018

    Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).

    By Margaret Patrick
  • uploads///Chart  Harvoni
    Company & Industry Overviews

    How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?

    Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.

    By Mike Benson
  • uploads///Chart  AMGN
    Miscellaneous

    The Rise of Amgen Stock in 2Q17

    Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Stock Rises on Higher Trading Volumes on June 8

    Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    What Are IBB’s Holdings’ Moving Averages?

    On May 27, 2016, 17% of the iShares Nasdaq Biotechnology ETF’s (IBB) stocks were trading above their 20-day moving averages.

    By Peter Neil
  • uploads///Chart
    Earnings Report

    Seattle Genetics’ Valuation: How Does It Compare?

    We believe that the enterprise-value-to-revenue multiple is the best measure for valuing Seattle Genetics (SGEN) and similar companies.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Mid-Caps: Medicines Company’s Carbavance, Fast-Track Status

    In a press release, the Medicines Company (MDCO) announced that the FDA has granted fast-track status to Carbavance for the treatment of complicated urinary tract infections.

    By Peter Neil
  • uploads///Pomalyst and Abraxane Revenue Part
    Earnings Report

    Pomalyst and Abraxane Revenues Are Critical for Celgene

    Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%

    Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.

    By Peter Neil
  • uploads///chart
    Macroeconomic Analysis

    Outlook for PBE’s Biotechnology Subsectors

    PBE’s biotechnology subsector is trading below its 100-day moving average by 3.0%, but above it 20-day and 50-day averages by 1.3% and 4.0%, respectively.

    By Ivan Kading
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Horizon Rose and Outperformed IBB’s Mid-Cap Stocks

    Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Myriad Genetics: Top Performer in the Biotechnology Subgroup

    Myriad Genetics (MYGN) rose 9% on November 4, 2015. It reported its fiscal 1Q16 results. Myriad Genetics reported revenue of $183.5 million.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Moving Averages of XBI’s Holdings Have Improved

    The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Grifols and Myriad Traded above the 100-Day Moving Averages

    Grifols (GRFS) only fell by 0.34%. It bucked the trend. There were talks that Moody’s upgraded the ratings from “negative” to “stable.”

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI’s Moving Averages: The Massive Plummet Last Week

    XBI’s moving average took a hit in the week ended September 25, and most of its stocks were trading below all the moving averages. Compared to the previous week, the fall was massive.

    By Peter Neil
  • uploads///LXK_Fit
    Fund Managers

    Iridian nearly doubles its holdings in Lexmark International

    Iridian Asset Management has increased its holdings in Lexmark International, Inc. (LXK) by 49%. This represents a 10.4% passive stake in the company.

    By Stuart McKenzie
  • uploads///AOL
    Fund Managers

    AOL gets 45% boost in Iridian Asset Management

    Iridian Asset Management’s position in AOL increased by 45%, increasing its shares from 5,075,812 to 7,369,542. Iridian has a 9.5% passive stake in AOL.

    By Stuart McKenzie
  • uploads///HALO_Portfolio
    Fund Managers

    Halozyme Therapeutics gets huge 60% increase in Iridian holdings

    Iridian Asset Management now holds 11,625,215 shares of Halozyme Therapeutics Inc. (HALO), a huge 60% increase. The fund has a 9% stake in the company.

    By Stuart McKenzie
  • uploads///OCR
    Fund Managers

    Omnicare gets 18% increase in Iridian

    Iridian increased its shares in Omnicare by approximately 18%, from 5,047,158 shares to 5,948,816. The fund holds a 6.1% passive stake in Omnicare.

    By Stuart McKenzie
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.